Abstract:Abstract Breast cancer is a complex disease with a high degree of inter-tumor heterogeneity. Subtyping the disease and identifying the genomic features driving these subtypes are critical for precision oncology for breast cancer. With increasing availability of single cell RNA-seq data and deconvolution methods, there is unmet need for identifying novel tumor-intrinsic subtypes based on deconvoluted tumor-specific expression profiles as well as novel bulk tumor subtypes based on bulk RNA-seq data. Drug response prediction based on tumor-intrinsic subtypes can be also potentially more robust than drug response prediction based on bulk subtypes because currently available CRISPR and drug screening data are mostly based on only cancer cell lines. Therefore, we applied consensus hierarchical clustering, Bayesian Non-negative Matrix Factorization (BayesNMF), and deconvolution methods to 1,058 TCGA breast cancer samples and identified seven bulk expression subtypes (S1-S7) and five tumor-specific expression subtypes (S1-S5). In order to characterize our subtypes, we first performed subtype association with previously characterized subtypes, including PAM50, HR status, and METABRIC IntClust subtypes. Notably, Luminal A and METABRIC IntClust 4ER+ breast cancer was further partitioned into our S1 and S5 bulk subtypes. We characterized the subtypes with pathway activity, TME deconvolution, and subtype-associated driver mutations. Our BayesNMF bulk and tumor-specific subtypes showed stronger association with prognosis than PAM50 subtypes, suggesting potential clinical utility of our subtypes. We projected BayesNMF to DepMap cell lines and CPTAC breast cancer samples to identify subtype-specific vulnerabilities and proteogenomic characterization of our subtypes, respectively. We also developed the method to predict CDK4 selective and CDK6 selective drug response in human breast tumor tissues by training the NMF models with CDK4 and CDK6 dependency scores and gene expression features in the DepMap cell lines. Our tumor-specific S5 subtype had significantly lower CDK4 response scores and significantly higher CDK6 response scores than others suggesting that this subtype, which is primarily triple-negative breast cancer, might be potentially a good subtype for CDK6 selective inhibitors. Additionally, our tumor-specific S4 subtype had significantly higher CDK4 response scores and significantly lower CDK6 response scores than others suggesting that this subtype might be a promising patient population for CDK4 selective inhibitors. We further applied machine learning methods to identify biomarkers that associate with subtypes and CDK4/CDK6 dependency scores using gene expression, mutations, and CNAs. Overall, our subtyping approach identifies clinically-relevant novel breast cancer subtypes with subtype-specific cancer vulnerabilities and therapeutic targets. Citation Format: Julie Karam, Paul Rejto, Jadwiga R. Bienkowska, Xinmeng J. Mu, Whijae Roh. Identification of tumor-specific breast cancer expression subtypes and subtype-specific drug response prediction. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4543.

Drug-driven Reclassification of Multiple Tumour Subtypes Reveals Intrinsic Molecular Concordance of Therapy Across Histologically Disparate Cancers

Therapeutic Response-Based Reclassification of Multiple Tumor Subtypes Reveals Intrinsic Molecular Concordance of Therapy Across Histologically Disparate Cancers

Identification of Molecular Subtypes for Integrated Multi-Omics Analysis for Use in Guiding Precision Medicine in Hepatocellular Carcinoma.

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines

Precision unveiled: Synergistic genomic landscapes in breast cancer—Integrating single‐cell analysis and decoding drug toxicity for elite prognostication and tailored therapeutics

Abstract 4543: Identification of tumor-specific breast cancer expression subtypes and subtype-specific drug response prediction

scPharm: identifying pharmacological subpopulations of single cells for precision medicine in cancers

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies

Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology

Single cell atlas reveals multilayered metabolic heterogeneity across tumour types

Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines

Single nucleotide and copy number variants of cancer driver genes inform drug response in multiple cancers

Abstract A136: Inferring therapeutic vulnerability within tumors through integration of pan-cancer cell line and single-cell transcriptomic profiles

Identification of molecular subtypes based on chromatin regulator-related genes and experimental verification of the role of ASCL1 in conferring chemotherapy resistance to breast cancer

Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy

Identifying Anti-Cancer Drug Response Related Genes Using an Integrative Analysis of Transcriptomic and Genomic Variations with Cell Line-Based Drug Perturbations.

Towards Pathway-Centric Cancer Therapies Via Pharmacogenomic Profiling Analysis of Erk Signalling Pathway

Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level

Machine learning and multi-omics data reveal driver gene-based molecular subtypes in hepatocellular carcinoma for precision treatment

Integrative Multiomics Analyses Identify Molecular Subtypes of Head and Neck Squamous Cell Carcinoma with Distinct Therapeutic Vulnerabilities

Defining subpopulations of differential drug response to reveal novel target populations